bluebird bio, Inc.
DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES
Last updated:
Abstract:
The present disclosure provides improved compositions for adoptive T cell therapies targeting CD33 for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith. The present disclosure also relates to adoptive T cell therapies targeting CD33 and another target antigen for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
Status:
Application
Type:
Utility
Filling date:
13 Dec 2019
Issue date:
27 Jan 2022